|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Verdecchia A, Francisci S, Brenner H, et
al: Recent cancer survival in Europe: a 2000-02 period analysis of
EUROCARE-4 data. Lancet Oncol. 8:784–796. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Osman A: MicroRNAs in health and disease -
basic science and clinical applications. Clinical laboratory.
58:393–402. 2012.
|
|
4
|
Zhao G, Cai C, Yang T, et al: MicroRNA-221
induces cell survival and cisplatin resistance through PI3K/Akt
pathway in human osteosarcoma. PLoS One. 8:e539062013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mendell JT and Olson EN: MicroRNAs in
stress signaling and human disease. Cell. 148:1172–1187. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang B, Pan X, Cobb GP and Anderson TA:
microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar
|
|
8
|
Dieckmann KP, Spiekermann M, Balks T, et
al: MicroRNAs miR-371-3 in serum as diagnostic tools in the
management of testicular germ cell tumours. Br J Cancer.
107:1754–1760. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takahashi M, Cuatrecasas M, Balaguer F, et
al: The clinical significance of MiR-148a as a predictive biomarker
in patients with advanced colorectal cancer. PLoS One.
7:e466842012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Meng W, Ye Z, Cui R, et al: MicroRNA-31
predicts the presence of lymph node metastases and survival in
patients with lung adenocarcinoma. Clin Cancer Res. 19:5423–5433.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu XH, Lu KH, Wang KM, et al:
MicroRNA-196a promotes non-small cell lung cancer cell
proliferation and invasion through targeting HOXA5. BMC Cancer.
12:3482012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Jiang Q, Xia N, Yang H and Hu C:
Decreased expression of microRNA-375 in nonsmall cell lung cancer
and its clinical significance. J Int Med Res. 40:1662–1669. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang XC, Wang W, Zhang ZB, Zhao J, Tan XG
and Luo JC: Overexpression of miRNA-21 promotes
radiation-resistance of non-small cell lung cancer. Radiat Oncol.
8:1462013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bian HB, Pan X, Yang JS, Wang ZX and De W:
Upregulation of microRNA-451 increases cisplatin sensitivity of
non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res.
30:202011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP
and Wei WI: Mature miR-184 as potential oncogenic microRNA of
squamous cell carcinoma of tongue. Clin Cancer Res. 14:2588–2592.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang L, Belaguli N and Berger DH: MicroRNA
and colorectal cancer. World J Surg. 33:638–646. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park JK, Henry JC, Jiang J, et al: miR-132
and miR-212 are increased in pancreatic cancer and target the
retinoblastoma tumor suppressor. Biochem Biophys Res Commun.
406:518–523. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Anand S, Majeti BK, Acevedo LM, et al:
MicroRNA-132-mediated loss of p120RasGAP activates the endothelium
to facilitate pathological angiogenesis. Nat Med. 16:909–914. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Calin GA, Liu CG, Sevignani C, et al:
MicroRNA profiling reveals distinct signatures in B cell chronic
lymphocytic leukemias. Proc Natl Acad Sci USA. 101:11755–11760.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wei X, Tan C, Tang C, et al: Epigenetic
repression of miR-132 expression by the hepatitis B virus × protein
in hepatitis B virus-related hepatocellular carcinoma. Cell Signal.
25:1037–1043. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Formosa A, Lena AM, Markert EK, et al: DNA
methylation silences miR-132 in prostate cancer. Oncogene.
32:127–134. 2013. View Article : Google Scholar
|
|
22
|
Li S, Meng H, Zhou F, et al: MicroRNA-132
is frequently down-regulated in ductal carcinoma in situ (DCIS) of
breast and acts as a tumor suppressor by inhibiting cell
proliferation. Pathol Res Pract. 209:179–183. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang J, Gao T, Tang J, Cai H, Lin L and Fu
S: Loss of microRNA-132 predicts poor prognosis in patients with
primary osteosarcoma. Mol Cell Biochem. 381:9–15. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Groome PA1, Bolejack V, Crowley JJ, et al;
IASLC International Staging Committee; Cancer Research and
Biostatistics; Observers to the Committee; Participating
Institutions. The IASLC Lung Cancer Staging Project: validation of
the proposals for revision of the T, N, and M descriptors and
consequent stage groupings in the forthcoming (seventh) edition of
the TNM classification of malignant tumours. J Thorac Oncol.
2:694–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wanet A, Tacheny A, Arnould T and Renard
P: miR-212/132 expression and functions: within and beyond the
neuronal compartment. Nucleic Acids Res. 40:4742–4753. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brennecke J, Stark A, Russell RB and Cohen
SM: Principles of microRNA-target recognition. PLoS Biol.
3:e852005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Krek A, Grun D, Poy MN, et al:
Combinatorial microRNA target predictions. Nat Genet. 37:495–500.
2005. View
Article : Google Scholar : PubMed/NCBI
|
